{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.4","upperLimit":"16.9","value":"9.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Progression free survival (PFS) was defined as the time from registration to progression or death of any cause. Progression free and alive patients were censored at the date of last follow-up. The median PFS with 95% CI was estimated using the Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Use of dasatinib (50 mg orally twice a day) in treatment of pts with previously treated malignant mesothelioma","id":"OG000","title":"Dasatinib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time from registration to progression or death (up to 3 years)","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"weeks"}